vTv Therapeutics Inc. (Nasdaq: VTVT) reported disappointing results from a Phase 3 STEADFAST study of its Alzheimer's treatment azeliragon sending the stock price plummeting $2.54 to close at $0.71.
Disappointing study results for vTv Therapeutics
April 10, 2018 at 17:42 PM EDT